Leerink Partners Maintains Outperform on Camp4 Therapeutics, Raises Price Target to $9

Leerink Partners analyst Mani Foroohar has maintained an 'Outperform' rating on Camp4 Therapeutics (NASDAQ: CAMP) and increased the price target from $8 to $9. This adjustment reflects a positive outlook on the company's performance.